新劲刚 reported revenue of ¥0.23B for the period ended 2026-06-30, +39.3% year on year. Net income was ¥0.04B, a 16.1% net margin on a 63.4% gross margin. The largest revenue line is 射频微波业务 at 97% of the total. Free cash flow for the period was ¥0.17B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.23B | +39.3% |
| Gross profit | ¥0.14B | — |
| Operating income | ¥0.04B | — |
| Net income | ¥0.04B | +223.3% |
| Gross margin | 63.4% | Net margin 16.1% |
| Revenue Q/Q | +46.9% | — |
| Segment | Revenue | Share |
|---|---|---|
| 射频微波业务 | ¥0.22B | 96.7% |
| 特殊应用领域材料 | ¥0.01B | 3.0% |
| 其他 | ¥0.00B | 0.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.08B | 36.6% |
| R&D | ¥0.02B | 9.8% |
| SG&A | ¥0.02B | 11.0% |
| Tax & other | ¥0.00B | 2.1% |
| Item | Amount |
|---|---|
| Total assets | ¥2.12B |
| Total liabilities | ¥0.29B |
| Shareholders' equity | ¥1.83B |
| Equity / assets | 86.4% |
| Operating cash flow | ¥0.17B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.17B |
| Cash conversion (OCF / net income) | 307% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
久吾高科 ・ 光莆股份 ・ 开立医疗 ・ 彩讯股份 ・ 中达安 ・ 同和药业 ・ 扬帆新材 ・ 广和通 ・ 凯普生物 ・ 德艺文创 ・ 正丹股份 ・ 透景生命
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies